President Donald Trump is advocating for a significant shift in the pharmaceutical industry by encouraging drugmakers to sell their products directly to consumers. This move aims to streamline the drug distribution process and potentially lower costs for patients. However, the initiative has raised concerns about conflicts of interest, as a company with ties to Trump’s family stands to gain from these changes.











